You are here:

darunavir (Prezista)

Advice

Following an abbreviated submission

darunavir (Prezista ) is accepted for use within NHS Scotland, co-administered with low dose ritonavir in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated children and adolescents, from the age of 6 years and at least 20kg body weight, who have failed on more than one regimen containing a protease inhibitor (PI).

Darunavir is listed in the British National Formulary for Children for the treatment of HIV resistant to other protease inhibitors. The Scottish Medicines Consortium has previously accepted this product for use in this indication in adults.

Drug Details

Drug Name: darunavir (Prezista)
SMC Drug ID: 604/10
Manufacturer: Tibotec (Janssen-Cilag Ltd)
Indication: HIV in children and adolescents
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 February 2010

Back